Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 5/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13173953 | 0.90 | NAMPT (0.40) | NAMPTACLYATRHDAC4CA2 | |
| SCHEMBL8063345 | 0.80 | CA2 (0.42) | ACLYCA2 | |
| SCHEMBL28047289 | 0.76 | LIMK2 (0.48) | NAMPTHDAC4CA2 | |
| SCHEMBL18434159 | 0.74 | NAMPT (0.39) | NAMPTATRHDAC4CYP11B2FOLH1 | |
| SCHEMBL8062228 | 0.73 | GSTO1 (0.48) | NAMPTACLY | |
| SCHEMBL16087963 | 0.73 | NAMPT (0.47) | NAMPTATRHDAC4CYP11B2HTR7 | |
| SCHEMBL13173954 | 0.68 | CA2 (0.42) | ACLYCA2 | |
| SCHEMBL12677943 | 0.67 | DAO (0.47) | NAMPTHDAC4HTR7TLR8TLR7 | |
| SCHEMBL4695349 | 0.66 | NAMPT (0.54) | NAMPTATRHDAC4CA2 | |
| SCHEMBL634452 | 0.66 | NAMPT (0.56) | NAMPTATRHDAC4FOLH1ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617208-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617208-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2190814-B1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | UNIV JOHNS HOPKINS (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2504003-B1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-11-26 | — | — | US | disclosed |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-11-26 | — | — | US | disclosed |
| US-9115064-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115064-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120258965-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-10-11 | — | — | US | disclosed |
| US-8227639-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227639-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011063339-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063400-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2009-06-25 | — | — | US | disclosed |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2009-06-25 | — | — | US | disclosed |
| WO-2009042970-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | JOHNS HOPKINS UNIVERSITY (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | NOS2, NOS3, NOS1 | NAMPT 686/4885ACLY 518/4885ATR 4208/4885 |
| US-20120258965-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | NAMPT 524/4885ACLY 730/4885ATR 3637/4885 |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | NAMPT 524/4885ACLY 730/4885ATR 3637/4885 |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | NOS2, NOS3, NOS1 | NAMPT 670/4885ACLY 1175/4885ATR 4617/4885 |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | NAMPT 524/4885ACLY 730/4885ATR 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.